Nektar Therapeutics’s recent filing unveils that its Officer Zalevsky Jonathan acquired Company’s shares for reported $7191.0 on May 19 ’25. In the deal valued at $0.67 per share,10,712 shares were bought.
Then, Wilson Mark Andrew bought 9,996 shares, generating $6,710 in total proceeds.
Before that, ROBIN HOWARD W bought 23,208 shares. Nektar Therapeutics shares valued at $15,580 were divested by the Officer at a price of $0.67 per share.
Jefferies upgraded its Nektar Therapeutics [NKTR] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who increased its forecast for the stock in mid March from “a Perform” to “an Outperform”. B. Riley Securities began covering NKTR with “Buy” recommendation on January 08, 2025. H.C. Wainwright started covering the stock on December 10, 2024. It rated NKTR as “a Buy”.
Price Performance Review of NKTR
On Monday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock jump 1.46% to $0.69. Over the last five days, the stock has lost -2.77%. Nektar Therapeutics shares have fallen nearly -25.27% since the year began. Nevertheless, the stocks have fallen -62.02% over the past one year.
How much short interest is there in Nektar Therapeutics?
A steep rise in short interest was recorded in Nektar Therapeutics stocks on 2025-04-30, growing by 1.16 million shares to a total of 8.93 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 7.77 million shares. There was a rise of 12.95%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 04, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $7 price target.
